(NASDAQ: ABEO) Abeona Therapeutics's forecast annual revenue growth rate of 247.4% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.12%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.11%.
Abeona Therapeutics's revenue in 2026 is $5,820,000.On average, 9 Wall Street analysts forecast ABEO's revenue for 2026 to be $4,570,824,772, with the lowest ABEO revenue forecast at $2,137,227,549, and the highest ABEO revenue forecast at $8,209,924,900. On average, 8 Wall Street analysts forecast ABEO's revenue for 2027 to be $9,714,307,636, with the lowest ABEO revenue forecast at $7,675,946,045, and the highest ABEO revenue forecast at $11,980,294,830.
In 2028, ABEO is forecast to generate $13,664,381,989 in revenue, with the lowest revenue forecast at $11,684,780,891 and the highest revenue forecast at $16,371,358,130.